Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Research article

Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?

Sabrina Ehnert1*, Jian Zhao2, Stefan Pscherer3, Thomas Freude1, Steven Dooley4, Andreas Kolk5, Ulrich Stöckle1, Andreas Klaus Nussler12 and Robert Hube6

Author affiliations

1 BG Trauma Center, Eberhard Karls Universität Tübingen, Schnarrenbergstr. 95, D-72076, Tübingen, Germany

2 Department of Traumatology, MRI, Technische Universität München, Ismaninger Str. 22, D-81675 München, Germany

3 Department Nephrology, Klinikum Traunstein, Kliniken Südostbayern AG, Cuno-Niggl-Str. 3, D-83278 Traunstein, Germany

4 Department of Medicine II, University Hospital Mannheim, Ruprecht-Karls-Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68175 Mannheim, Germany

5 Department of Oro- and Maxillofacial Surgery, MRI, Technische Universität München, Str. 22, D-81675 München, Germany

6 Department of Orthopaedic Surgery, OCM-Clinic Munich, Steinerstr. 6, D-81368 München, Germany

For all author emails, please log on.

Citation and License

BMC Medicine 2012, 10:101  doi:10.1186/1741-7015-10-101

Published: 7 September 2012

Abstract

Background

Bone morphogenic proteins (BMPs) play a key role in bone formation. Consequently, it was expected that topical application of recombinant human (rh)BMP-2 and rhBMP-7 would improve the healing of complex fractures. However, up to 36% of fracture patients do not respond to this therapy. There are hints that a systemic increase in transforming growth factor β1 (TGFβ1) interferes with beneficial BMP effects. Therefore, in the present work we investigated the influence of rhTGFβ1 on rhBMP signaling in primary human osteoblasts, with the aim of more specifically delineating the underlying regulatory mechanisms.

Methods

BMP signaling was detected by adenoviral Smad-binding-element-reporter assays. Gene expression was determined by reverse transcription polymerase chain reaction (RT-PCR) and confirmed at the protein level by western blot. Histone deacetylase (HDAC) activity was determined using a test kit. Data sets were compared by one-way analysis of variance.

Results

Our findings showed that Smad1/5/8-mediated rhBMP-2 and rhBMP-7 signaling is completely blocked by rhTGFβ1. We then investigated expression levels of genes involved in BMP signaling and regulation (for example, Smad1/5/8, TGFβ receptors type I and II, noggin, sclerostin, BMP and activin receptor membrane bound inhibitor (BAMBI), v-ski sarcoma viral oncogene homolog (Ski), Ski-related novel protein N (SnoN) and Smad ubiquitination regulatory factors (Smurfs)) and confirmed the expression of regulated genes at the protein level. Smad7 and SnoN were significantly induced by rhTGFβ1 treatment while expression of Smad1, Smad6, TGFβRII and activin receptor-like kinase 1 (Alk1) was reduced. Elevated SnoN expression was accompanied by increased HDAC activity. Addition of an HDAC inhibitor, namely valproic acid, fully abolished the inhibitory effect of rhTGFβ1 on rhBMP-2 and rhBMP-7 signaling.

Conclusions

rhTGFβ1 effectively blocks rhBMP signaling in osteoblasts. As possible mechanism, we postulate an induction of SnoN that increases HDAC activity and thereby reduces the expression of factors required for efficient BMP signaling. Thus, inhibition of HDAC activity may support bone healing during rhBMP therapy in patients with elevated TGFβ serum levels.

Keywords:
alkaline phosphatase; mineralized matrix; osteoblasts; rhBMPs; TGFβ